A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results suggested that this 'gene signature' could be used to identify a subclass of lung tumors that is more likely to be eradicated by immunotherapies.
